Dr. Elizabeth Finger

Associate Professor, University of Western Ontario

Dr. Elizabeth Finger is an Associate Professor in the Department of Clinical Neurological Sciences at The University of Western Ontario (London, Ontario, Canada). She is a Neurologist at the Parkwood Institute, and a Scientist at Lawson Health Research Institute. She received a Bachelor of Science in Biochemistry from Harvard University in Cambridge, Massachusetts. She completed an MD at Cornell University in New York City in 2000. Dr. Finger then completed an internship in internal medicine at Massachusetts General Hospital, followed by Neurology residency and a year as chief resident at Masschusetts General Hospital and Brigham and Women’s Hospital in Boston, Massachusetts. Following residency Dr. Finger completed a 3 year clinical research fellowship in the Unit on Affective and Cognitive Neuroscience at the National Institute of Mental Health in Bethesda, Maryland. She is the recipient of  resident teaching awards from Harvard University (2003, 2004), Special Act Awards for Fellows at the NIH (2006, 2007), and the Early Researcher Award from the Ministry of Research and Innovation of Ontario (2015-2019).

Dr. Finger’s research focuses on advancing the diagnosis and treatment of neuropsychiatric disorders including Frontotemporal Dementia through detailed study of the cognitive, neural, and genetic substrates of abnormal decision-making, emotion, and social behavior. The research program combines neuropsychological tasks with neuroimaging, pharmacologic challenges, and genetics to delineate the cognitive and neural systems affected in patients with Frontotemporal dementia and their at-risk family members.

At the Cognitive Neurology and Alzheimer’s Disease Research Centre at Parkwood her clinic is specialized in the diagnosis and treatment of patients with neurodegenerative disease including Frontotemporal Dementia and related disorders, Alzheimer’s disease, and Lewy Body Dementia. She has participated in many academic and industry sponsored clinical trials including Rember (LMTM) in Frontotemporal Dementia (TauRx; Ongoing), the NIH sponsored Alzheimer’s disease Neuroimaging Initiative (ADNI; Ongoing), and the CIHR and Weston Foundation sponsored Genetic Neuroimaging in Frontotemporal Dementia initiative (GENFI; Ongoing).  The trial presented here is an extension of her research interests, as it focuses on evaluation of the hormone oxytocin as a novel treatment approach for deficits of social apathy, empathy and related social behaviours in patients with Frontotemporal Dementia.

Dr. Elizabeth Finger Grants